Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouMost Gulf skincare sourcing disputes do not start with a failed batch. They start with a clause nobody read. A brand ends a relationship with its OEM, asks for its production specifications, and discovers…
Most Gulf skincare sourcing disputes do not start with a failed batch. They start with a clause nobody read. A brand ends a relationship with its OEM, asks for its production specifications, and discovers one of three things: the formula belongs to the factory, the process instructions were never written down, or the documents exist but nobody is contractually obliged to hand them over. By then, the leverage is gone. This guide is written for brand owners and sourcing managers in the GCC who want to answer a single question before signing: if this relationship ends, what exactly can we walk away with, and who is obliged to deliver it? It is informational only, not legal advice — contract wording should be reviewed by counsel in your jurisdiction.
“Can we get our production specifications at exit?” is usually three separate rights bundled into one sentence. Negotiate them separately, because factories concede them at very different rates.
Many contracts grant the first, quietly deny the second, and never mention the third. A brand that owns 100% of a formula but has no transfer obligation typically loses six to nine months and one to two trial batches relearning what the original factory already knew.
Never sign a clause that refers to “the specifications” without a schedule that lists them line by line. Vague definitions are where exit disputes live. Use a table like this as the starting point for your annex — and mark which items you require at signature versus at exit.
| Specification item | What it actually controls | What to request in the annex | Typical negotiation difficulty |
|---|---|---|---|
| Finished product specification | Release testing: appearance, pH, viscosity, odour, specific gravity, fill weight, micro limits | Signed spec sheet with test methods and acceptance ranges | Low |
| Qualitative formula (INCI) | Labeling and regulatory notification | Ingredient list matching the exact notified version | Low–medium |
| Quantitative formula (% w/w, with ranges) | Actual reproduction of the product | Full composition, or escrowed composition released on defined triggers | High |
| Manufacturing process instructions | Emulsification temperature, homogenisation speed and time, cooling ramp, addition order, vacuum | Master batch record with parameters, not just step names | High |
| Raw material list | Supply continuity, cost, and approved alternates | Supplier, grade, and pre-approved substitute per critical material | Medium–high |
| Analytical and microbiological methods | Whether a second lab can verify the same result | Preservative efficacy (challenge test) protocol, stability protocol, method references | Medium |
| Stability and compatibility data | Heat and humidity performance in Gulf storage and transit | Accelerated and real-time reports, plus packaging compatibility report | Medium |
| Packaging specification | Filling, leakage, pump dose, decoration, label adhesion | Drawings, tolerances, 2D/3D files, decoration artwork, tooling list | Medium |
| Artwork and label files | Bilingual Arabic/English compliance and reprints | Editable source files and print-ready PDFs, owned by the brand | Low |
| Regulatory dossier inputs | Market access continuity in the GCC | Safety assessment inputs, PIF-supporting data, notification data package | Medium |
| Batch records, CoA archive, retention samples | Audit readiness and dispute resolution | Copies of batch records, CoA archive, retention sample period and handover | Low–medium |
This distinction decides most negotiations. Factories rarely refuse to transfer custom work; they refuse to hand over the platform bases they spent years developing and sell to many clients.
A workable compromise for a platform base: the brand receives a defined technical dossier (qualitative formula, process parameters, key material list) at signature, with the quantitative formula held by an escrow agent and released on a defined trigger. This is common in flavours and fragrances and increasingly used in skincare.
An exit clause without a trigger definition is a negotiation, not a right. Confirm in writing what activates the transfer obligation:
| Clause term | What to aim for in the wording | Why it matters |
|---|---|---|
| Definitions schedule | Named list of documents, formats, and languages that constitute the “Specification Pack” | Removes the argument about whether a CoA counts as a specification |
| Delivery obligation | Pack delivered within 10–15 business days of a valid trigger; digital files plus signed hard copies | Prevents a slow handover from becoming a de facto refusal |
| Licence to background IP | Perpetual, irrevocable on payment, sub-licensable to a successor manufacturer | Without sub-licensing, the documents are legally unusable elsewhere |
| Transfer assistance | Defined engineer hours, trial batch support, and side-by-side reference samples | Turns a document dump into a reproducible product |
| Tooling and moulds | Registered tooling schedule with ownership, location, photographs, and retrieval rights | Tooling is the most common form of practical hostage-taking |
| Regulatory handover | Brand or its own local agent holds notification accounts; dossier transferred at exit | Market access should not be contingent on the factory relationship |
| Dispute forum | Agreed seat, language, and injunctive relief for breach of confidentiality or IP terms | Enforcement speed often matters more than the merits |
Expect resistance on quantitative formulas and on process parameters, which are usually treated as core know-how. Realistic trades:
Symptom: You ask for the formula and receive an INCI list.
Root cause: The contract said “formula” without defining composition, ranges, or format.
Prevention: Annex the Specification Pack with a named quantitative document and an escrow fallback.
Evidence to request: Signed annex plus the escrow agreement and release conditions.
Symptom: The second factory’s trial batch separates, discolours, or smells different.
Root cause: Process parameters were never documented — temperatures, homogenisation speed and time, addition order, and cooling ramp existed only in operator habit.
Prevention: Require a master batch record with numerical parameters, not step names.
Evidence to request: Executed batch record from the last three commercial lots, with in-process checkpoints.
Symptom: Leakage, pump dose drift, or label lift after two months in Gulf storage.
Root cause: Packaging compatibility failure — the bottle, pump, valve, or adhesive was approved on a stock component without testing against your actual formula in real heat and humidity.
Prevention: Make compatibility and transit testing a contractual gate before bulk production, and own the packaging specification.
Evidence to request: Packaging compatibility report, transit simulation report, adhesion test results, and the drawing files with tolerances.
Symptom: At exit, the CoA, SDS, stability report, or micro data are missing or version-mismatched.
Root cause: Documentation failure — no controlled document register tied to a specific formula revision, so labels, notifications, and test data drifted apart.
Prevention: Require a revision-numbered document register per SKU, updated at every formula or supplier change.
Evidence to request: Document register, SDS revision log, stability and challenge test reports matching the current revision.
Symptom: Moulds, print cylinders, or decoration tooling cannot be retrieved.
Root cause: Tooling was never registered as brand-owned property, and the supplier treated it as their asset.
Prevention: A tooling schedule with location, serial numbers, photographs, and a retrieval right.
Evidence to request: Tooling register plus paid tooling invoices in the brand’s name.
Symptom: The product cannot be re-notified in the new market setup.
Root cause: The notification account and safety assessment inputs were held by the factory or its agent, not the brand.
Prevention: Brand-controlled accounts and contractual dossier handover at exit.
Evidence to request: Account ownership confirmation and the dossier data package.
Symptom: A competitor launches a near-identical product from the same base.
Root cause: No exclusivity term, or exclusivity limited to a period too short to recover development cost.
Prevention: A written exclusivity schedule covering territory, category, and duration.
Evidence to request: Executed exclusivity schedule with defined carve-outs for the factory’s stock lines.
| Phase | Buyer action | Manufacturer action | Evidence produced |
|---|---|---|---|
| Weeks 0–2 | Draft the Specification Pack annex and exit triggers | Confirm which items are transferable and which are licensed | Agreed annex with format and language list |
| Weeks 2–4 | Negotiate ownership split and transfer fee | Disclose third-party IP constraints | IP schedule and licence wording |
| Weeks 4–6 | Set up escrow if quantitative formula is withheld | Deposit documents with the escrow agent | Escrow agreement and deposit confirmation |
| Weeks 6–10 | Approve packaging specification and Arabic artwork files | Issue compatibility and transit test reports | Packaging spec, artwork source files, test reports |
| Weeks 10–14 | Complete dossier review with your regulatory consultant | Hand over PIF-supporting and notification data | Dossier index and handover receipt |
| Weeks 14–20 | Run a second-source trial batch as a rehearsal | Provide engineer support and reference samples | Trial batch record and comparative stability data |
Only if the contract says so. Without a defined and agreed clause, you can generally expect the finished product specification, the qualitative INCI list, and batch documentation — not the quantitative composition, which many factories treat as background IP. The practical route is to negotiate the right before signing, or to accept escrow with objective release conditions.
A specification describes what the finished product must measure — pH, viscosity, appearance, fill weight, micro limits. A formula describes how to make it. A specification lets you verify a batch; a formula lets you reproduce one elsewhere. Most buyers need both, but only the specification is usually granted without argument.
Fall back to three parallel actions: secure a complete documented specification pack so a new partner can reverse-engineer efficiently, qualify a second source for packaging early, and negotiate a defined transition period with engineer support. Also confirm whether any part of the process is licensed from a third party that could supply you directly.
There is no blanket statutory right that overrides your contract in the way many brand owners assume. Outcomes depend on the contract terms, the applicable law, and where you can realistically enforce. Confirm the position with counsel qualified in your chosen governing law before relying on it.
Expect a technology transfer fee, a licence fee for any background IP, and an escrow fee if used. Negotiating these as a schedule at signature is materially cheaper than negotiating them under pressure at termination, when your production has already stopped.
If you are sourcing skincare for a Gulf launch and want the specification and handover questions resolved at quotation stage rather than at exit, send us your brief: target markets, SKU list and formats, positioning, packaging direction, and timeline. You will get a scoped response covering formulation route, documentation deliverables, and the handover terms we commit to in writing.
Informational only, not legal advice. Contract terms and regulatory requirements vary by market and change over time; verify with qualified counsel and your local regulatory agent before signing or launching.